Medication Management, LLC

Summary

Medication Management, LLC is a medical facility located in Greensboro, North Carolina. This center is recognized for care of Rheumatoid Arthritis, Systemic Lupus Erythematosus, Cardiovascular Disease, Type 2 Diabetes, Heart Failure and other specialties. Medication Management, LLC is involved with conducting 65 clinical trials across 98 conditions. There are 5 research doctors associated with this hospital, such as Jagadeesh Ganji, Walter Pharr, MD, Tauseef G Syed, and James Donald Franklin.

Top PIs

Clinical Trials running at Medication Management, LLC

Cardiovascular Disease

Obesity

Heart Failure

Atherosclerosis

Systemic Lupus Erythematosus

Cutaneous Lupus Erythematosus

Diabetes

C. diff infection

Coronary Heart Disease

Heart Attack

Olpasiran

for Cardiovascular Disease

The primary objective is to evaluate the effect of olpasiran, compared to placebo, on the risk for coronary heart disease death (CHD death), myocardial infarction, or urgent coronary revascularization in participants at risk for a first major cardiovascular event with elevated lipoprotein(a) (Lp\[a\]).

Recruiting

1 award

Phase 3

2 criteria

Retatrutide

for Obesity

The main purpose of this study is to determine if retatrutide can significantly lower the incidence of serious heart-related complications or prevent the worsening of kidney function. The trial will enroll adults with body mass index 27 kg/m\^2 or higher and Atherosclerotic Cardiovascular Disease and/or chronic kidney disease. The study will last for about 5 years. Participants will have up to 27 clinic visits with the study doctor.

Recruiting

1 award

Phase 3

2 criteria

Lepodisiran

for Cardiovascular Disease

This trial is testing lepodisiran, a medication given as an injection under the skin. It targets people with high levels of lipoprotein(a) who have cardiovascular disease or are at risk of heart attack or stroke. The medication works by lowering lipoprotein(a) levels to reduce the risk of these cardiovascular events.

Recruiting

1 award

Phase 3